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placebo-controlled study in patients with persistent asthma (randomized n ¼ 360)
maintained on low to moderate doses of inhaled corticosteroids. Patients were
randomized to receive ciclesonide 80 or 320 mg (ex-actuator doses, equivalent to 100
and 400 mg ex-valve, respectively) or placebo once daily in the morning via metered-
dose inhaler for 12 weeks. Morning peak expiratory flow was maintained throughout
the treatment period in patients treated with ciclesonide and decreased significantly
in patients treated with placebo (P ¼ 0:0003). Ciclesonide (80 and 320 mg)
significantly increased forced expiratory volume in 1 s from baseline (0.13 and
0.19 L increases, respectively; Po0:01); improvements were superior versus placebo
(P ¼ 0:0044 for 80 mg ciclesonide; Po0:0001 for 320 mg ciclesonide). The probability
of losing efficacy decreased in a dose-dependent manner (55% for placebo, 38% for
ciclesonide 80 mg, 23% for ciclesonide 320 mg). Asthma symptom scores and rescue
medication use were unchanged with ciclesonide and significantly worsened with
placebo. The incidence of adverse events was comparable in all treatment groups
and no cortisol suppression was observed. Therefore, ciclesonide 80 and 320 mg
administered once daily was a safe and effective maintenance treatment for
patients with persistent asthma.
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Airway inflammation is the underlying cause of
airway hyperactivity in asthma, and inhaled corti-
costeroids (ICS) are the proven mainstay of anti-
inflammatory therapy for asthma.1 The effective-
ness of these agents is dependent on a variety of
pharmacologic properties including lung deposition
and glucocorticoid receptor binding affinity. Lung
deposition is heavily influenced by the inhaler
system employed.2,3 For example, ICS metered-
dose inhalers (MDI) using a hydrofluoroalkane (HFA)
propellant and a solution ICS formulation provide
greater penetration into peripheral airways than
ICS traditionally administered via chlorofluorocar-
bon propellants.4–7 Solution ICS deliver fine parti-
cles on inhalation, resulting in low oropharyngeal
deposition and high lung deposition with even
distribution compared with suspension formulations
that achieve coarse particles.
Receptor binding affinity varies among the avail-
able ICS, and the newest and most efficacious
agents exhibit high steroid receptor binding affinity
at very low concentrations. In addition to the
implications for clinical efficacy, receptor binding is
responsible for the side effects associated with the
use of corticosteroids, both when applied topically
and when systemically available. Systemic compli-
cations, associated with frequent and/or high doses
of ICS, include cortisol suppression and interfer-
ence with bone growth.8–10 Additionally, ICS ad-
ministered by either MDI or dry powder inhaler can
leave residual steroid in the oropharyngeal cavity
and can be associated with local side effects, such
as dysphonia and oral candidiasis.
Because available ICS are associated with local
and systemic side effects, a need exists for improved
ICS that provide optimal anti-inflammatory effects
and asthma control with an improved safety and
tolerability. Because glucocorticoids exert their
activity by binding to the glucocorticoid receptor,
new agents must be designed with optimal physico-
chemical properties to circumvent the inability of
ICS to discriminate between wanted and unwanted
effects. These new agents should afford high
receptor affinity, high lung-targeted deposition,
low oropharyngeal deposition, and low systemic
availability, resulting in appropriate advantages in
delivery, efficacy, tolerability, and safety.
Ciclesonide, a nonhalogenated glucocorticoster-
oid, was designed to exhibit favorable pharmaco-
kinetic properties to yield an improved therapeutic
ratio compared with available ICS.11–13 Ciclesonide
is delivered as a solution to the lung using a HFA-
MDI, and yields high pulmonary deposition with
minimal oropharyngeal deposition.14 Moreover,ciclesonide is administered as a parent compound
with a relative glucocorticoid receptor binding
affinity of 12 and is converted in the lung by
esterases to yield an active metabolite, desisobu-
tyryl-ciclesonide (des-CIC), with a high relative
binding affinity of 1212 (compared with a relative
binding affinity of 100 for dexamethasone).15–17
Furthermore, ciclesonide and des-CIC are highly
lipophilic, and des-CIC undergoes fatty acid con-
jugation in the lung.18 High lung deposition, high
receptor affinity, high lipophilicity, and lipid con-
jugation of des-CIC in the lung are attributes that
may allow ciclesonide treatment to yield optimal
efficacy, safety, and tolerability with once-daily
dosing. Therefore, the aim of this 12-week study
was to assess the efficacy and safety of 2 doses of
ciclesonide, 100 and 400 mg, once daily (QD) in the
morning compared with placebo and to evaluate
the dose-response relationship of ciclesonide in
patients with persistent asthma.Methods
Patients
Male or female outpatients 18–70 years of age with
a history of asthma (forced expiratory volume in 1 s
(FEV1) between 60% and 95% of predicted normal)
as defined by the British Thoracic Society (1993)
who were otherwise in good health were eligible
for study enrollment.19 All patients received main-
tenance ICS therapy, including beclomethasone
dipropionate (BDP) (400–800 mg per day), budeso-
nide (400–800 mg per day), or fluticasone propio-
nate (200–500 mg per day), and were required to be
on a stable dosage regimen for at least 4 weeks
before randomization. For randomization into the
treatment period, patients were required to have
an FEV1 between 60% and 90% predicted and not
meet any criteria for ‘‘lack of efficacy.’’ Moreover,
to exclude patients with chronic obstructive pul-
monary disease (COPD), patients must have demon-
strated reversible airway obstruction20 (FEV1
increase X15% in response to salbutamol
200–400 mg) during the baseline period or within 3
months prior to start of the baseline period or a
diurnal peak expiratory flow (PEF) variabilityX 15%
on at least 3 of the 7 days preceding the first
randomization visit.
Patients were excluded if they had any severe
chronic disease or condition in which the use of ICS
were contraindicated or had an exacerbation of
asthma, chest infection, or hospitalization because
of asthma within 6 weeks before entry into the
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pulmonary disease or other relevant lung diseases
were also excluded. Premenopausal women were
excluded if they were pregnant or lactating or if
they were of childbearing potential and not using
reliable contraception. Patients were excluded if
they smoked410 cigarettes per day. The following
medications were not allowed before entry into or
during the study: oral and injectable glucocorti-
costeroids (6 weeks before entry); nasal and
topically applied glucocorticosteroids (4 weeks
before entry); and long-acting b2-agonists (4 weeks
before entry).Study design
Fifty-one study centers in the United Kingdom and
Canada were involved in this randomized, double-
blind, parallel-group, placebo-controlled study.
The ethics committee of each participating center
approved the study, and all patients gave written
informed consent to participate. The study was
performed in accordance with the principles of
Good Clinical Practice and the revised declaration
of Helsinki (Somerset West, October 1996). The
study included 3 periods: a 2-week baseline period,
a 12-week treatment period, and a follow-up
period, if required. In the baseline period, patients
continued their previous dose of ICS. At the end of
the baseline period, patients were randomized to
receive ciclesonide 80 mg (ex-actuator [delivered
dose], equivalent to 100 mg ex-valve [metered
dose]), ciclesonide 320 mg (ex-actuator, equivalent
to 400 mg ex-valve), or placebo, each given QD in
the morning via HFA-MDI. Throughout the study, use
of asthma medications other than rescue medica-
tion (salbutamol) was not permitted. Physical
examination and electrocardiogram were per-
formed at baseline and final visit.Efficacy measures
Primary efficacy variables were (1) change in
morning PEF from baseline to end of treatment
determined from patients’ diaries and (2) occur-
rence of predefined ‘‘lack of efficacy’’ during the 12
weeks of treatment. ‘‘Lack of efficacy’’ was defined
as the presence or occurrence of any 1 of a series of
criteria including asthma exacerbation, a decrease
in FEV1 of at least 20% of the baseline value or to less
than 50% of predicted normal, a nighttime asthma
score of X2 in at least 4 of 7 nights or of X3 in at
least 2 of 7 nights directly preceding a visit, a
daytime asthma score of X3 on at least 4 of 7 days
directly preceding a visit, or another deteriorationin pulmonary function that, in the judgment of the
investigator, compromised a patient’s health. The
asthma score sum was based on a 5-point scale
where a score of 0 represented no asthma-related
symptoms and a score of 4 represented the highest
discomfort resulting from asthma-related symptoms
(i.e. awake most of the night because of asthma or
unable to carry out daytime activities because of
asthma). Patients and investigators assessed the
subjective efficacy of study treatment on a 4-point
scale ranging from very effective (good control of
asthma symptoms) to ineffective (poor control of
asthma symptoms). Patients meeting the criteria for
‘‘lack of efficacy’’ at any time were discontinued
from the study and considered dropouts.
Secondary efficacy variables were FEV1, forced
vital capacity (FVC), and PEF (from spirome-
try)—all measured at end of treatment and at
scheduled visits—as well as morning and evening
PEF, asthma symptom scores, symptom-free days,
rescue medication-free days, rescue medication
use based on daily diary entries, and efficacy rating
by the patient and investigator. Throughout the
trial, patients were required to maintain a daily
diary of morning and evening PEF, use of rescue
medication, and of night- and daytime asthma
symptoms. Lung function tests and standard
laboratory tests were performed at baseline, at
randomization, and after 2, 4, 8, and 12 weeks of
treatment with the study medication.
Lung function tests at clinic visits after the
baseline visit were to be performed within790min
of the time they were performed at the baseline
visit. Patients were instructed to withhold their
rescue medication for at least 4 h before lung
function testing. For FEV1, FVC, and PEF, the
highest value from at least 3 technically satisfac-
tory attempts was used for analysis. Predicted
values were calculated according to the formula of
the European Community for Coal and Steel.21Safety evaluation
An inquiry into adverse events (AEs) was conducted
at all clinic visits after baseline. Morning serum and
24-h urine were collected and analyzed for cortisol
to determine effects of ciclesonide on the hypotha-
lamic-pituitary-adrenal (HPA) axis. Urine was col-
lected in any 24-h period within the 7 days
preceding start of treatment or week 12.Statistics
The sample size calculation was based on the ratio of
value after 12 weeks of therapy to value at baseline
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a ¼ 0:025 (1-sided) and a power of 80% for detecting
superiority of ciclesonide 320mg QD compared with
placebo (assuming that values at week 12 exceeded
those at baseline by 12.75%). This resulted in a
sample size of 76 valid cases (corresponding to 90
intent-to-treat patients) per group.
The intent-to-treat analysis (all patients receiv-
ing study medication at least once) was chosen for
purposes of efficacy analysis. For primary efficacy
variables, 1-sided tests between treatments were
performed. The level for the type I error rate for 1-
sided tests was set at 2.5%, i.e. a ¼ 0:025, 1-sided,
corresponding to a ¼ 0:05, 2-sided. To confirm
between-group comparison of two primary vari-
ables, a Bonferroni adjustment to a ¼ 0.0125
(0.025/2), 1-sided (corresponding to a ¼ 0:025, 2-
sided), was performed. For both primary endpoints,
the last available value, irrespective of premature
termination or exclusion from the study, was used
for the statistical analysis. With regard to all lung
function variables, an analysis of covariance ac-
cording to Ebbutt and Frith (1998) was applied,
with the difference from the baseline value as the
dependent variable; treatment, center, and gender
as factors; and age and the baseline lung function
value as covariates.
The secondary variables of change in morning/
evening PEF at multiple visits and changes in the
spirometric variables (FEV1, FVC, PEF) at endpoint
and weeks 2, 4, 8, and 12, all versus baseline, were
analyzed using analysis of covariance in a similar
way to the primary variable of morning PEF.
However, there was no adjustment of the a level
for multiplicity of variables.Table 1 Demographic and baseline characteristics.
Characteristics Placebo
Patients, n 125
Sex (male/female) (%) 41/59
Age, yearsa 37 (18–70
Nonsmokers/(ex)smokers (%) 59/41
FEV1 (L) 2.5570.7
FEV1 (% predicted) 7879
Reversibility change in FEV1 (%) 20.979.7
Morning PEF (diary) (L/min) 412792
Morning PEF (diary) (% predicted) 90715
PEF variability (%) 7.175.1
Data of the intent-to-treat population are presented as mean7SD
Ciclesonide 80 and 320-mg are ex-actuator doses.
CIC ¼ ciclesonide; QD ¼ once daily; FEV1 ¼ forced expiratory vol
aFor age, median (range) is given.Subjective efficacy ratings, symptom scores,
rescue medication use, and safety assessment data
were analyzed in a descriptive manner. Changes
between baseline and 12-week serum and urine
cortisol levels were characterized by median,
means, 95% confidence intervals, and 2-sided P-
values for differences within and between treat-
ment groups.Results
Patient population
Among 488 patients enrolled, 360 were randomized
to receive ciclesonide 80 mg ðn ¼ 120Þ, ciclesonide
320 mg ðn ¼ 115Þ, or placebo ðn ¼ 125Þ. Demo-
graphic and baseline characteristics are presented
in Table 1. The majority of the patients (98%) had
mild to moderate asthma (mild 47%, moderate 51%)
based on FEV1 percent predicted, with 2% experi-
encing severe asthma. Before the study entry,
patients had been receiving ICS at mean doses of
619, 648, and 599 mg/day BDP equivalent for the
placebo, 80- and 320-mg/day ciclesonide groups,
respectively. A total of 145 patients discontinued
the study early: 72 (58%) in the placebo group, 46
(38%) in the ciclesonide 80-mg group, and 27 (23%)
in the ciclesonide 320-mg group. The primary reason
for discontinuation in all three groups was lack of
efficacy, which occurred in 53 (42%) patients in the
placebo group, 37 (31%) patients in the ciclesonide
80-mg group, and 21 (18%) patients in the cicleso-
nide 320-mg group. Other reasons for discontinua-CIC
80 mg QD 320 mg QD
120 115
44/56 49/51
) 40 (18–70) 45 (18–70)
53/47 55/45
2 2.5170.73 2.5670.68
7879 7878
22.278.7 23.4713.9
4087104 417796
89715 90715
7.476.1 7.175.4
.
ume in 1 s; PEF ¼ peak expiratory flow.
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Figure 2 Change in morning PEF after 12 weeks of
treatment based on last available value: Morning PEF did
not significantly change in either ciclesonide group; in
contrast, there was a statistically significant decrease in
morning PEF after 12 weeks in patients receiving placebo
(*P ¼ 0:0003 versus baseline). In addition, both cicleso-
nide doses were superior to placebo with regard to the
change from baseline. Intent-to-treat population
(n ¼ 119 for placebo, n ¼ 113 for CIC 80 mg, n ¼ 113 for
320 mg) data are based on least-squares means. Cicleso-
nide 80 and 320 mg are ex-actuator doses. yPo0.01 versus
placebo. PEF ¼ peak expiratory flow; CIC ¼ ciclesonide;
QD ¼ once daily.
Efficacy and safety of ciclesonide 1279tion included major protocol violations and medical
and nonmedical reasons. Only 1 patient withdrew
because of an AE (in the ciclesonide 80-mg group).
Pulmonary function
Mean morning PEF increased slightly in patients
receiving ciclesonide (Figs. 1 and 2, and Table 2). In
contrast, morning PEF declined significantly in
patients treated with placebo (18 L/min; P ¼
0:0003 versus baseline; Fig. 2). The differences
between both ciclesonide groups and placebo were
statistically significant (ciclesonide 80 mg QD,
P ¼ 0:0012; ciclesonide 320 mg QD, P ¼ 0:0006),
whereas there was no statistically significant
difference between the ciclesonide treatment
groups.
Placebo treatment caused a slight decrease in
FEV1 (0.03 L, P ¼ 0:54 versus baseline), whereas
ciclesonide (80 and 320 mg QD) treatment signifi-
cantly increased FEV1: +0.13 L (P ¼ 0:0032 versus
baseline) and +0.19 L (Po0:0001 versus baseline),
respectively (Table 2). The difference between
each ciclesonide dose and placebo was significant
for ciclesonide 80 mg QD (P ¼ 0:0044) and for
ciclesonide 320 mg QD (P ¼ 0:0001). There was a
trend toward dose-dependent increase in FEV1 with
ciclesonide. However, the difference between the
two ciclesonide doses was not statistically signifi-
cant.
Both ciclesonide doses achieved a statistically
significant increase in FVC after 12 weeks
(P ¼ 0:0002 versus baseline) with a mean change
of more than 0.19 L (Table 2). Furthermore,Figure 1 Change in morning PEF (diary) during 12 weeks
of treatment: Morning PEF was maintained throughout
the treatment period in patients receiving ciclesonide
while it decreased in patients receiving placebo. Intent-
to-treat population; n represents the number of patients
with available data for each time point; data are based
on least-squares means. PEF ¼ peak expiratory flow;
CIC ¼ ciclesonide; QD ¼ once daily. Ciclesonide 80 and
320 mg are ex-actuator doses.improvements in both ciclesonide groups were
superior versus placebo (ciclesonide 80 mg QD,
P ¼ 0:0203; ciclesonide 320 mg QD, P ¼ 0:0197).
Similarly, ciclesonide treatment significantly in-
creased evening PEF. In contrast, evening PEF
decreased in patients treated with placebo (12
L/min; P ¼ 0:0069 versus baseline). Improvements
with both doses of ciclesonide were superior to
placebo (ciclesonide 80 mg QD, P ¼ 0:0121; cicleso-
nide 320 mg QD, P ¼ 0:0048), and there were no
clinically relevant or statistically significant differ-
ences between the two ciclesonide groups. The
improvement in spirometric PEF was statistically
significant in both groups when compared with
placebo, but the difference between the two
ciclesonide groups was not statistically significant.Asthma symptom scores and rescue
medication use
Asthma symptom scores (score sum) and use of
rescue medication remained stable in patients
receiving either dose of ciclesonide (Table 3). In
contrast, patients receiving placebo experienced an
increase in asthma symptoms (Po0:0001 versus
baseline) and use of rescue medication (P ¼ 0:0009
versus baseline). Differences between both cicleso-
nide doses and placebo were statistically significant
with respect to change from baseline in asthma
ARTICLE IN PRESS
Table 2 Change in pulmonary function after 12 weeks of treatment.
Parameter Placebo CIC
80 mg QD 320 mg QD
Spirometry
FEV1 (L)
Baseline 2.55 2.55 2.55
Change 0.03 +0.13 +0.19
P-value versus baseline 0.54 0.0032 o0.0001
P-value versus placebo — 0.0044 0.0001
FVC (L)
Baseline 3.11 3.11 3.11
Change +0.04 +0.19 +0.20
P-value versus baseline 0.44 0.0002 0.0002
P-value versus placebo — 0.0203 0.0197
PEF (L/min)
Baseline 390.6 390.6 390.6
Change +0.89 +22.37 +38.27
P-value versus baseline NS 0.0043 0.0001
P-value versus placebo — 0.0292 0.0002
Diary
Morning PEF (L/min)
Baseline 413 413 413
Change 18 +2 +3
P-value versus baseline 0.0003 0.6795 0.4687
P-value versus placebo — 0.0012 0.0006
Evening PEF (L/min)
Baseline 425 425 425
Change 12 +2 +4
P-value versus baseline 0.0069 0.6904 0.3918
P-value versus placebo — 0.0121 0.0048
Data of the intent-to-treat population are presented as least-squares means using analysis of covariance.
Ciclesonide 80 and 320mg are ex-actuator doses.
No significant differences between ciclesonide groups with respect to change from baseline.
CIC ¼ ciclesonide; QD ¼ once daily; FEV1 ¼ forced expiratory volume in 1 s; FVC ¼ forced vital capacity;
PEF ¼ peak expiratory flow.
C.G. Langdon et al.1280symptom score (Po0:0001) and use of rescue
medication (Po0:01). The differences between the
two ciclesonide doses were not significant.
Day- and nighttime asthma symptom scores,
assessed separately, decreased in a manner similar
to that of the combined analysis. Ciclesonide
treatment maintained both daytime and nighttime
asthma symptom scores versus baseline, while both
scores significantly increased (i.e. symptoms wor-
sened) for patients in the placebo group (Po0:0001
versus baseline) (Table 3). Differences in asthma
symptom scores between both ciclesonide doses
and placebo were statistically significant
(Pp0:0001 for both) and there were no significant
differences between the two ciclesonide doses.
Symptom-free and rescue medication-free days
significantly improved versus placebo in patients
treated with ciclesonide (Fig. 3). Symptom-free
days and rescue medication-free days were morethan five- and nine-fold greater, respectively, for
ciclesonide 320 mg QD versus placebo (Pp0:001 for
both). The difference in symptom-free days be-
tween the ciclesonide and placebo treatment
groups was also statistically significant (and
P ¼ 0:0297). Finally, the number of rescue medica-
tion-free days trended toward improvement with
ciclesonide 80 mg QD (mean, 37 days versus 26 days
for placebo; P ¼ 0:0592). There were no statisti-
cally significant differences between the two
ciclesonide doses for either symptom-free days or
rescue medication-free days (P ¼ 0:0592 and
0.1605, respectively).
More patients and investigators rated ciclesonide
as effective after 12 weeks of therapy compared
with placebo. Ciclesonide was rated as effective or
very effective by 69% of patients in the 80-mg group
and by 76% of patients in the 320-mg group and
similar effectiveness ratings were reported by
ARTICLE IN PRESS
Table 3 Change in asthma symptom scores and rescue medication use after 12 weeks of treatment.
Parameter Placebo CIC
80 mg QD 320 mg QD
Total asthma symptom score
Baseline 1.15 1.43 1.00
Change +1.00 0 0
P-value versus baseline o0.0001 0.4773 0.9342
P-value versus placebo — o 0.0001 o 0.0001
Daytime symptom score
Baseline 0.76 0.86 0.57
Change +0.43 0 0
P-value versus baseline o0.0001 0.9604 0.1935
P-value versus placebo — 0.0001 o 0.0001
Nighttime symptom score
Baseline 0.43 0.57 0.31
Change +0.43 0 0
P-value versus baseline o0.0001 0.0882 0.0480
P-value versus placebo — o 0.0001 0.0001
Rescue medication use (diary) (puffs/day)
Baseline 1.93 2.14 1.43
Change +0.50 0 0
P-value versus baseline 0.0009 0.4784 0.6417
P-value versus placebo — 0.0019 0.0038
Data for the intent-to-treat population are presented as medians.
Ciclesonide 80 and 320mg are ex-actuator doses.
No significant differences between ciclesonide groups with respect to change from baseline.
CIC ¼ ciclesonide; QD ¼ once daily.
Figure 3 Symptom- and rescue-medication-free days:
The median number of symptom-free days and rescue-
medication-free days were higher in patients treated
with ciclesonide compared with placebo with the
differences reaching statistical significance for both
measures in the ciclesonide 320-mg group and for
symptom-free days in the ciclesonide 80-mg group.
Intent-to-treat population (n ¼ 120 for placebo, n ¼
118 for CIC 80 mg, n ¼ 114 for 320 mg) data are presented.
Ciclesonide 80 and 320 mg are ex-actuator doses.
CIC ¼ ciclesonide; QD ¼ once daily. *P ¼ 0:0297 versus
placebo; yPo0:0001; zP ¼ 0:0010. Differences between
the two ciclesonide doses for either symptom-free days
or rescue medication-free days were not significant
(P ¼ 0:0592 and 0.1605, respectively).
Efficacy and safety of ciclesonide 1281investigators (67% and 68% rated ciclesonide as
effective for the 80 and 320-mg doses, respectively).
In contrast, placebo was regarded as effective by
only 42% of patients and 47% of investigators.Lack of efficacy
There was a dose-dependent decrease in the
probability of experiencing lack of efficacy during
the study, from 50% for placebo to 36% for
ciclesonide 80 mg QD and 23% for ciclesonide
320 mg QD (Fig. 4). Statistically significant differ-
ences were found between ciclesonide 320 mg QD
and placebo (Po0:0001 for the log-rank test for
probability that there is a trend across the three
treatment groups), between ciclesonide 80 mg QD
and placebo (Pp0:0052), and between ciclesonide
320 mg QD and ciclesonide 80 mg QD (P ¼ 0:0087).Safety
Adverse events
Ciclesonide was well tolerated during the 12 weeks
of treatment. All AEs reported with a frequency
ARTICLE IN PRESS
Table 4 Frequently reported adverse events
(X5% of patients).
Adverse event Patients, n (%)
Placebo CIC 80mg QD CIC 320 mg QD
ðn ¼ 125Þ ðn ¼ 120Þ ðn ¼ 115Þ
Asthmaa 26 (21) 7 (6) 9 (8)
URI 14 (11) 21 (18) 14 (12)
Rhinitis 7 (6) 9 (8) 9 (8)
Headache 4 (3) 6 (5) 8 (7)
Back pain 2 (2) 4 (3) 6 (5)
Sore throat 0 (0) 3 (3) 6 (5)
Ciclesonide 80 and 320 mg are ex-actuator doses.
CIC ¼ ciclesonide; QD ¼ once daily; URI ¼ upper respira-
tory tract infection.
aWorsening of asthma, including asthma exacerbations.
Figure 5 Changes in creatinine-corrected urinary corti-
sol levels after 12 weeks of treatment: There were no
statistically significant changes from baseline for any of
the treatment groups (P ¼ 0:6707, placebo; P ¼ 0:9403,
CIC 80 mg; P ¼ 0:2711, CIC 320 mg) and the differences
between groups with regard to the change from baseline
were not statistically significant (P ¼ 0:6860, CIC 80 mg;
P ¼ 0:3120, CIC 320 mg). Intent-to-treat population
(n ¼ 45 for placebo, n ¼ 60 for CIC 80 mg, n ¼ 77 for
320 mg) data are presented as means. Ciclesonide 80 and
320 mg are ex-actuator doses. CIC ¼ ciclesonide;
QD ¼ once daily.
Figure 4 Probability of experiencing lack of efficacy
during 12 weeks of treatment: Both ciclesonide doses
were superior to placebo with regard to the percentage
of patients meeting ‘‘lack of efficacy’’ criteria over the
duration of the study. Intent-to-treat population data are
based on least-squares means. The difference between
ciclesonide doses was statistically significant
(P ¼ 0:0087). Ciclesonide 80 and 320 mg are ex-actuator
doses. *Po0:0001 for CIC 320 mg QD versus placebo (log-
rank test for trend); yPp0:0052 for CIC 80 mg QD versus
placebo. CIC ¼ ciclesonide; QD ¼ once daily.
C.G. Langdon et al.1282X5% are listed in Table 4. Most of the AEs reported
were mild or moderate in intensity. The incidence
of AEs assessed as ‘‘likely related’’ to study
medication was low in all three treatment groups
and not dose related: 6% for placebo, 6% for
ciclesonide 80 mg QD, and 4% for ciclesonide
320 mg QD. These AEs included headache, nausea,
increased cough, dry skin, and altered taste. There
were no serious AEs judged as related to study
medication. Vital signs, electrocardiograms, and
clinical laboratory parameters did not reveal any
clinically significant changes or apparent trends
resulting from treatment with ciclesonide.
The incidence of local, oral AEs in the ciclesonide
treatment groups was low and comparable with
placebo. Sore throat and pharyngitis were the most
common local AEs. Pharyngitis occurred in 1% of
patients treated with placebo, in 2% of patients in
the ciclesonide 80-mg group, and in 2% of patients in
the ciclesonide 320-mg group. There was 1 case of
voice alteration in the ciclesonide 320-mg group,
and there were no cases of oral candidiasis in any
treatment group.
Effect on cortisol
Serum and urinary cortisol levels did not signifi-
cantly change from baseline in any treatment group
(Fig. 5). In contrast with the cortisol suppression
typically observed with other ICS, serum and urine
cortisol levels were either unaffected or increased
after 12 weeks of ciclesonide treatment. Mean
serum cortisol levels (nmol/L) at baseline and after
12 weeks of therapy were, for the placebo andciclesonide 80- and 320-mg QD groups, respectively,
443 and 459, 429 and 449, and 420 and 414. Mean
urinary cortisol levels (nmol/mmol creatinine) at
baseline and after 12 weeks of therapy are
depicted in Fig. 5. Small variations in serum and
24-h urine cortisol levels were seen in all treatment
ARTICLE IN PRESS
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ment groups were not statistically significant.Discussion
This 12-week study demonstrates that ciclesonide
80 or 320 mg, administered once daily in the
morning via HFA-MDI, was superior to placebo for
maintenance of lung function control in patients
with persistent asthma. Morning PEF assessed by
diary was maintained with ciclesonide therapy in
this patient population with primarily mild to
moderate asthma, all of whom had previously been
treated with ICS, whereas deterioration was ob-
served with placebo. Furthermore, PEF by spiro-
metry improved with ciclesonide therapy when
compared with placebo. These results demonstrate
that ciclesonide is an effective anti-inflammatory
maintenance therapy even with daily doses as low
as 80 mg. Furthermore, there were statistically
significant improvements from baseline achieved
with ciclesonide for spirometric measures of lung
function (FEV1 and FVC), and these improvements
were significantly superior to lung function mea-
sures in patients treated with placebo. Finally,
compared with the placebo group, patients receiv-
ing ciclesonide were significantly less likely to
experience lack of efficacy (i.e. asthma deteriora-
tion).
Similarly, patients treated with ciclesonide had
no deterioration in asthma symptom scores and use
of rescue medication compared with a statistically
significant worsening of asthma symptoms and
increased use of rescue medication observed in
patients receiving placebo. Therefore, the patient
population enrolled in this study, required treat-
ment with potent anti-inflammatory therapy to
maintain control of asthma symptoms. Based on the
recent Global Initiative for Chronic Obstructive
Lung Disease (GOLD) criteria, the study inclusion
criteria may have allowed the inclusion of a small
number of patients with mild COPD to partici-
pate.20 Despite this, patients receiving ciclesonide
had significantly superior lung function measures
and control of asthma symptoms compared with
patients receiving placebo.
One of the objectives of the present study was to
define a dose-response relationship for ciclesonide
in the treatment of asthma. The study demon-
strated that there was a statistically significant
dose-response relationship for lack of efficacy and a
trend towards a dose-dependent effect for FEV1,
PEF (spirometry) and the number of symptom-free
days and rescue medication-free days. Previousstudies with ICS have shown that the dose-response
curves may differ for various efficacy variables.
Studies have shown that a four-fold or greater
difference in dose is required to show a statistically
significant difference in effect on commonly mea-
sured outcomes; however, even such large dose
increases are not always associated with consistent
dose-dependent improvements in efficacy.22,23
Therefore, some efficacy variables may not be
sensitive enough to dose-dependent clinical im-
provements. The data presented herein suggest
that a composite endpoint, such as ‘‘lack of
efficacy,’’ may be a suitable measure for establish-
ing a dose-response relationship of ICS compared
with individual pulmonary function endpoints as
indicated by the statistically significant dose-
response demonstrated by ciclesonide.
The results of this trial suggest that a once-daily
dosing schedule for ciclesonide is suitable for
control of symptoms in patients with persistent
asthma. Ciclesonide was administered in the
morning, and its beneficial effects persisted
throughout the night and into the following morn-
ing, as evidenced by stability of morning PEF
values. In addition, statistically significant differ-
ences between ciclesonide and placebo were
observed for both daytime and nighttime asthma
symptom scores. These measurements remained
stable for patients treated with ciclesonide but
increased significantly (i.e. symptoms worsened)
with placebo. The activity of ciclesonide over this
24-h period may be related to the fatty acid
conjugation of des-CIC in the lung. The lipophilicity
and lipid conjugation profile of ciclesonide and des-
CIC prolong pulmonary retention, yielding a long
duration of action by providing a slow-release pool
for the continued supply of des-CIC within the lung.
Therefore, the long duration of lung function
effects of ciclesonide may permit once-daily dosing
at doses as low as 80 mg. Furthermore, ciclesonide
formulation as a solution aerosol administered via
HFA-MDI and the high affinity of des-CIC for the
glucocorticoid receptor allow high lung deposition
and even distribution of ciclesonide throughout the
lungs, even in the small airways, to provide potent
anti-inflammatory activity.
In this 12-week study, once-daily treatment with
ciclesonide (80 and 320 mg) was well tolerated. The
incidence of AEs for both ciclesonide doses was
comparable with placebo. There was only 1 case of
voice alteration in patients who received cicleso-
nide, and there were no cases of oral candidiasis,
both of which are local oropharyngeal side effects
typically encountered with other ICS. The low
incidence of these side effects is likely related to
the minimal activation of ciclesonide in the
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tive glucocorticoid receptor affinity (12 relative to
a reference of 100 for dexamethasone),17 but is
converted, primarily in the lung, by esterases to
yield its active metabolite des-CIC that has a high
relative glucocorticoid receptor affinity (1200).16
Because the passage of ciclesonide through the
oropharynx is primarily in the inactive form, the
risk of local side effects is minimal.
Previous studies have reported that the incidence
of side effects increases with elevations in ICS
dose.9 Furthermore, the risk of side effects has also
been shown to increase with once-daily ICS admin-
istration compared with splitting the dose via
twice-daily administration.26 However, the present
investigation demonstrates that ciclesonide does
not increase the risk for side effects with dose
escalation or once-daily administration. Cortisol
levels, a surrogate marker for HPA axis effects, did
not change significantly after treatment with
ciclesonide or placebo and, notably, serum and
urine cortisol levels with 80 mg ciclesonide were
comparable with levels in patients treated with a
four-fold higher dose (320 mg). These data agree
with previous studies showing no effect of cicleso-
nide on the HPA axis.27,28 The high degree of
protein binding of des-CIC in the systemic circula-
tion29 and the rapid hepatic metabolism of des-
CIC30 minimizes systemic exposure to the active
metabolite, thereby reducing systemic side effects.
Therefore, this study and others suggest that
ciclesonide has a dose-independent safety profile
that is comparable with placebo.
The results of this study confirm that, collec-
tively, optimal physiochemical properties of cicle-
sonide provide high lung-targeted, anti-
inflammatory activity with minimal oropharyngeal
and systemic side effects. Ciclesonide was shown to
be effective at daily doses as low as 80 mg
administered as a solution formulation via HFA-
MDI in patients with persistent asthma who had
been using daily ICS doses in the range of
approximately 600 mg BDP equivalent. Moreover,
the occurrence of adverse events with both doses
of ciclesonide was low, dose independent, and
comparable with placebo. Furthermore, there was
no systemic effect of ciclesonide on cortisol
secretion; ciclesonide at both doses did not cause
cortisol suppression and cortisol levels were com-
parable with placebo. Therefore, ciclesonide is an
important addition to the armamentarium of anti-
inflammatory agents currently available for the
treatment of asthma, offering effective mainte-
nance of lung function and control of asthma
symptoms with a safety profile that appears to be
improved relative to currently available ICS.Acknowledgments
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